Association of patient risk factors and frequency of nevus-associated cutaneous melanomas

JAMA Dermatology

Volumn 152, Issue 3, 2016, Pages 291-298

  Haenssle, Holger A ^a,b   Mograby, Nerjes ^a   Ngassa, Anni ^a   Buhl, Timo ^a   Emmert, Steffen ^a,b   Schön, Michael P ^a   Rosenberger, Albert ^a,c   Bertsch, Hans Peter ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER ROSTOCK   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRESLOW THICKNESS; CANCER DIAGNOSIS; CANCER RISK; CANCER SURGERY; CLINICAL EVALUATION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS MELANOMA; CUTANEOUS PARAMETERS; DISEASE ASSOCIATION; EPILUMINESCENCE MICROSCOPY; FEMALE; HAIR COLOR; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEVUS ASSOCIATED CUTANEOUS MELANOMA; NEVUS COUNT; OBSERVATIONAL STUDY; ONCOLOGICAL PARAMETERS; PATIENT MONITORING; PHOTOGRAPHY; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RISK ASSESSMENT; SEQUENTIAL DIGITAL DERMOSCOPY; SEX DIFFERENCE; SKIN TYPE; TOTAL BODY PHOTOGRAPHY; TUMOR INVASION; TUMOR LOCALIZATION; TUMOR VOLUME; CELL TRANSFORMATION; MELANOMA; NEVUS, PIGMENTED; PATHOLOGY; RISK FACTOR; SKIN; SKIN NEOPLASMS;

ADULT; AGED; CELL TRANSFORMATION, NEOPLASTIC; DERMOSCOPY; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEVUS, PIGMENTED; PROSPECTIVE STUDIES; RISK FACTORS; SKIN; SKIN NEOPLASMS;

EID: 84962176275     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.3775     Document Type: Article

References (36)

1. Koh HK. Melanoma screening: focusing the public health journey. Arch Dermatol. 2007; 143(1): 101-103.
2. Nikolaou V, Stratigos AJ Emerging trends in the epidemiology of melanoma. Br J Dermatol. 2014; 170(1):11-19.
3. Haenssle HA, Vente C, Bertsch H.P., et al. Results of a surveillance programme for patients at high risk of malignant melanoma using digital and conventional dermoscopy. Eur J Cancer Prev. 2004; 13(2):133-138.
4. Haenssle HA, Krueger U, Vente C., et al. Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. J Invest Dermatol. 2006; 126(5):980-985.
5. Haenssle HA, Korpas B, Hansen-Hagge C, et al. Selection of patients for long-term surveillance with digital dermoscopy by assessment of melanoma risk factors. Arch Dermatol. 2010; 146(3):257-264.
6. Gandini S, Sera F, Cattaruzza M.S., et al. Meta-analysis of risk factors for cutaneous melanoma: I: common and atypical naevi. Eur J Cancer. 2005; 41(1):28-44.
7. Goldstein AM, Tucker MA Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev. 2013; 22(4):528-532.
8. Rhodes AR, Sober AJ, Mihm M.C., Fitzpatrick TB. Possible risk factors for primary cutaneous melanoma [abstract]. Clin Res. 1980; 28:252A.
9. Elder DE, Greene MH, Bondi E.E., Clark WH. Acquired melanocytic nevi and melanoma: the dysplastic nevus syndrome. In: Ackerman AB, ed. Pathology of Malignant Melanoma. New York, NY: Masson; 1981:185-216.
10. Weatherhead SC, Lawrence CM Melanoma screening clinics: are we detecting more melanomas or reassuring the worried well? Br J Dermatol. 2006; 154(3):539-541.
11. Jones WM, Williams WJ, Roberts M.M., Davies K. Malignant melanoma of the skin: prognostic value of clinical features and the role of treatment in 111 cases. Br J Cancer. 1968; 22(3):437-451.
12. Friedman RJ, Rigel DS, Kopf A.W., et al. Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi. Arch Dermatol. 1983; 119(6):455-462.
13. Stolz W, Schmoeckel C, Landthaler M., Braun-Falco O. Association of early malignant melanoma with nevocytic nevi. Cancer. 1989; 63(3): 550-555.
14. Kaddu S, Smolle J, Zenahlik P., Hofmann-Wellenhof R, Kerl H. Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and prognosis. Melanoma Res. 2002; 12(3):271-278.
15. Sagebiel RW. Melanocytic nevi in histologic association with primary cutaneous melanoma of superficial spreading and nodular types: effect of tumor thickness. J Invest Dermatol. 1993; 100(3): 322S-325S.
16. Massi D, Carli P, Franchi A., Santucci M. Naevus-associated melanomas: cause or chance? Melanoma Res. 1999; 9(1):85-91.
17. Bevona C, Goggins W, Quinn T., Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch Dermatol. 2003; 139(12):1620-1624.
18. Skender-Kalnenas T.M., English DR, Heenan PJ Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma? J Am Acad Dermatol. 1995; 33(6):1000-1007.
19. Rhodes AR, Harrist TJ, Day C.L., Mihm MC Jr, Fitzpatrick TB, Sober AJ. Dysplastic melanocytic nevi in histologic association with 234 primary cutaneous melanomas. J Am Acad Dermatol. 1983; 9 (4):563-574.
20. Couperus M, Rucker RC Histopathological diagnosis of malignant melanoma. AMA Arch Derm Syphilol. 1954; 70(2):199-216.
21. Krüger S., Garbe C, Büttner P, Stadler R., Guggenmoos-Holzmann I, Orfanos CE. Epidemiologic evidence for the role of melanocytic nevi as risk markers and direct precursors of cutaneous malignant melanoma: results of a case control study in melanoma patients and nonmelanoma control subjects. J Am Acad Dermatol. 1992; 26(6):920-926.
22. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20):2191-2194.
23. Garbe C, Büttner P, Weiss J., et al. Associated factors in the prevalence of more than 50 common melanocytic nevi, atypical melanocytic nevi, and actinic lentigines: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol. 1994; 102(5):700-705.
24. Tucker MA, Halpern A, Holly E.A., et al. Clinically recognized dysplastic nevi: a central risk factor for cutaneous melanoma. JAMA. 1997; 277(18): 1439-1444.
25. Fusaro RM, Lynch HT The FAMMM syndrome: epidemiology and surveillance strategies. Cancer Invest. 2000; 18(7):670-680.
26. Argenziano G, Fabbrocini G, Carli P., De Giorgi V, Sammarco E, Delfino M. Epiluminescence microscopy for the diagnosis of doubtful melanocytic skin lesions: comparison of the ABCD rule of dermatoscopy and a new 7-point checklist based on pattern analysis. Arch Dermatol. 1998; 134 (12):1563-1570.
27. Ascierto PA, Palmieri G, Celentano E., et al. Sensitivity and specificity of epiluminescence microscopy: evaluation on a sample of 2731 excised cutaneous pigmented lesions: the Melanoma Cooperative Study. Br J Dermatol. 2000; 142(5): 893-898.
28. Salerni G, Terán T, Puig S., et al. Meta-analysis of digital dermoscopy follow-up of melanocytic skin lesions: a study on behalf of the International Dermoscopy Society. J Eur Acad Dermatol Venereol. 2013; 27(7):805-814.
29. Carli P, Massi D, Santucci M., Biggeri A, Giannotti B. Cutaneous melanoma histologically associated with a nevus and melanoma de novo have a different profile of risk: results from a case-control study. J Am Acad Dermatol. 1999; 40(4):549-557.
30. Kopf AW, Welkovich B, Frankel R.E., et al. Thickness of malignant melanoma: global analysis of related factors. J Dermatol Surg Oncol. 1987; 13(4):345-390, 401-420.
31. Marks R, Dorevitch AP, Mason G. Do all melanomas come from "moles"? a study of the histological association between melanocytic naevi and melanoma. Australas J Dermatol. 1990; 31(2): 77-80.
32. Greene MH. The genetics of hereditary melanoma and nevi: 1998 update. Cancer. 1999; 86 (11)(suppl):2464-2477.
33. MacKie RM, Freudenberger T, Aitchison TC Personal risk-factor chart for cutaneous melanoma. Lancet. 1989; 2(8661):487-490.
34. Masri GD, Clark WH Jr, Guerry D IV, Halpern A, Thompson CJ, Elder DE Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol. 1990; 22(6, pt 1):1042-1048.
35. Bataille V. Genetics of familial and sporadic melanoma. Clin Exp Dermatol. 2000; 25(6):464-470.
36. Bishop JA, Wachsmuth RC, Harland M, et al Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J Invest Dermatol. 2000; 114(1):28-33.